Published: May 10, 2021
May 10, 2021 11:00 UTC
Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care
1
FIGARO-DKD is the second positive Phase III study within the finerenone study program in CKD and T2D to meet its primary endpoint
1,2,3
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure). The Phase III FIGARO-DKD study included more patients with earlier stage CKD and T2D compared to the FIDELIO-DKD stu
Abdelaziz Ali Elsanjak MD is recognized by Continental Who s Who
News provided by
Share this article
ROANOKE, Va., May 10, 2021 /PRNewswire/
Abdelaziz Ali Elsanjak MD is being recognized by Continental Who s Who as a Top Nephrologist for his professional achievements in the medical field and his dedication to serving the community at Valley Nephrology Associates.
Abdelaziz Ali Elsanjak MD
For over 40 years, Valley Nephrology Associates has been highly committed to providing the best comprehensive kidney care to their patients in Southwest Virginia. The well-trained providers specialize in the treatment of kidney disorders, kidney disease, and high blood pressure. At Valley Nephrology Associates, they offer Chronic Care Management, Dialysis Access Treatments, Home Hemodialysis, and Pediatric Nephrology, to name a few.
E-Mail
Washington, DC (May 6, 2021) An ongoing debate is focused on race-based algorithms in medicine such as an adjustment for Black race in equations that estimate individuals kidney function. A study appearing in an upcoming issue of JASN examines the impact of dropping this race adjustment on patient care.
Assessing individuals kidney function plays an important role in screening for and treating kidney diseases, and current methods primarily rely on estimating kidney function, what s known as a patient s estimated glomerular filtration rate (eGFR), from the serum creatinine level. The most commonly used eGFR equation includes an adjustment for Black versus non-Black race, resulting in higher eGFR values for a Black patient compared with a non-Black patient. Recognizing that race is a social and not a biological construct, however, several healthcare institutions no longer report eGFR with an adjustment for Black race, and ASN and the National Kidney Foundation have recen
The Ledger
DOCTOR S CHOICE HOME CARE
Doctor’s Choice Home Care recently relocated its Lakeland and Brandon offices. The Lakeland office is now located at 4740 Cleveland Heights Blvd., Suite No. 3, 33813. The Brandon office is now located at 1397 Oakfield Drive, 33511. Doctor’s Choice is an accredited and Medicare-certified agency providing patient-focused home health care services in Florida including skilled nursing, physical therapy, occupational therapy, speech therapy, medical social worker aide and home health aide. 863-283-6286 or visit www.doctorschoicefl.com.
NEMOURS AT LAKELAND REGIONAL HEALTH
Olga Zand, M.D., FAAP, a board-certified, pediatric intensivist and pediatric hospitalist, will serve as director of the Pediatric Intensive Care Unit for Nemours at Lakeland Regional Health. Zand completed her fellowship in pediatric critical care at Women and Children’s Hospital of Buffalo – State University of New York at Buffalo School of Medicine. She completed a res